• Home
  • Latest News
  • New announcement by MeiraGTx marks 1 million sq ft of property solutions delivered by Shannon Group at Shannon Free Zone since 2014

New announcement by MeiraGTx marks 1 million sq ft of property solutions delivered by Shannon Group at Shannon Free Zone since 2014

SHANNON, IRELAND August 6, 2020: Shannon Group welcomes the announcement by MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, of their decision to locate multi-million euro facilities at Shannon Free Zone in Co. Clare.

The new leading-edge facilities are currently under construction and are being developed by Shannon Group’s subsidiary company, Shannon Commercial Properties. They will comprise 94,000 sq ft in two separate buildings designed to meet global regulatory requirements, including the cGMP, required by the U.S. Food and Drug Administration (FDA).

The units at Shannon Free Zone will be used for the manufacture of MeiraGTx viral vectors for gene therapies and the plasmid DNA that is one of the starting materials in viral vector production.

These facilities are part of a major development programme by Shannon Commercial Properties which by end of 2020 will have seen them delivered almost 1 million sq ft of new or refurbished office, aviation and industrial commercial property facilities at Shannon Free Zone, since Shannon Group was formed in 2014.

Welcoming Meira to Shannon, Rose Hynes Chairman of Shannon Group, stated that their decision to locate in Shannon Free Zone and the anticipated job creation validates the decision by Shannon Group to commence this development programme in the Shannon Free Zone and comes on top of significant investments by Jaguar Land Rover, Edwards Lifesciences, Engine Lease Finance and GE Sensing in commercial property solutions developed by Shannon Group in the Shannon Free Zone.

MeiraGTx has selected Shannon as the site of its second current good manufacturing practices, or cGMP viral vector manufacturing facility and cGMP plasmid production facility. These facilities will be designed for the manufacture of commercial-grade gene therapies in a fully integrated manner supported by MeiraGTx’s global quality assurance organisation.
 
MeiraGTx expects the Irish facilities, to provide additional flexibility as well as further large-scale capacity for clinical and commercial supply of its gene therapy product candidates from pre-clinical stages through clinical trials and potential commercialisation. This project is supported by the Irish Government through IDA Ireland and further information in relation to the facility will follow.
 
The plasmid production facility is expected to be operational by year-end 2020, while the viral vector manufacturing facility is expected to be operational by year-end 2021.